AlphAIAlphAI — Financial news for AI agents
tradingview.comOCT 201 min read$MBRX

Moleculin Biotech, Inc. (MBRX) Completes Part A Enrollment; Full Data Readout Planned Q1 2027

Moleculin Biotech (MBRX) completed Part A enrollment in its Phase 2/3 MIRACLE trial of Annamycin plus HiDAC for R/R AML, with interim efficacy data encouraging. Full 90-patient Part A data readout is expected in Q1 2027, contingent on securing financing. The company is tracking progress and setting a data timeline for the pivotal trial.

Original reporting
tradingview.com
Published Oct 20, 2026, 12:12 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 20, 2026, 12:20 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Moleculin Biotech, Inc. (MBRX) Completes Part A Enrollment; Full Data Readout Planned Q1 2027 — source image
Source · tradingview.com
Decision brief

The 30-second read

$MBRXNeutralMed
01

Why it matters

The enrollment milestone is a forward‑looking catalyst; investors will monitor data readout and financing news.

02

Market read

Trial progress is a material event for a micro‑cap biotech, offering a medium‑term trade idea.

03

What to watch

Potential competition from other AML therapies and regulatory timelines could affect the catalyst.

Relevance 7/10Novelty 7/10Timing: Q1 2027 data readout pending

Background

Moleculin Biotech (NASDAQ: MBRX) is developing an AML therapy (Annamycin + HiDAC) and is in a pivotal Phase 2/3 trial.

Company-level read

Ticker impact

$MBRXNeutralHigh confidence
Context

Moleculin Biotech announced completion of Part A enrollment in its Phase 2/3 MIRACLE trial, with full data readout expected in Q1 2027.

Expected impact

potential upward pressure if Part A data are positive, but uncertainty around financing may keep the stock volatile.

Evidence & confidence

Trial milestones are material for biotech stocks; investors price in future data and funding risk.

Market effects

Sector

Adds a positive catalyst to the AML biotech sub‑sector, may lift peer valuations.

Regional

Limited to US biotech investors; no broader regional effect.

Global

Minimal global impact beyond niche oncology investors.

Counterpoint

What could challenge this read

If financing for Part B fails, the trial could stall, leading to a sharp downside.

Key entities

  • company
    Moleculin Biotech, Inc.

    Biotech firm developing AML therapy.

Read at source← All news

StoryMoleculin completes Part A enrollment in MIRACLE AML trial, full data slated for Q1 2027

Related articles

OCT 20
$MBRXMed

Moleculin Biotech completes enrollment in AML trial phase

Moleculin Biotech (MBRX) completed enrollment in Part A of its Phase 2/3 MIRACLE trial for Annamycin in treating relapsed/refractory acute myeloid leukemia. Interim efficacy results were reported, with full data expected in Q1 2027. The company plans to proceed with Part B and seeks additional financing for trials. Annamycin is also being developed for soft tissue sarcoma lung metastases.

investing.com2 min
OCT 20
$MBRXHighAI 8/10

Moleculin Releases Next CEO Corner Segment Highlighting Recent Progress in Annamycin MIRACLE Trial

Moleculin Biotech (MBRX) released a CEO Corner segment discussing progress in its Phase 2/3 MIRACLE trial for Annamycin in treating relapsed or refractory AML. Enrollment in Part A is complete, with interim results showing promise. Full data is expected in Q1 2027. The company also outlined plans for Part B expansion and broader applications for Annamycin.

stocktitan.net2 min
SEP 29
$MBRXLow

Moleculin Biotech Completes Enrollment in Part A of Phase 2/3 R/R AML MIRACLE Trial, Keeping Program on Track for Q1 2027 Data Readout

Moleculin Biotech, Inc. (MBRX) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 Moleculin Biotech Completes Enrollment in Part A of Phase 2/3 R/R AML MIRACLE Trial, Keeping Program on Track for Q1 2027 Data Readout – Rapid completion of Part A enrollment underscores strong operational execution and investigator engagement in relapsed or refracto

SEC EDGAR 8-K2 min
SEP 28
$MBRXMedAI 8/10

Moleculin Advances Annamycin Following Peer-Reviewed Cardiac Safety Data

Moleculin Biotech (MBRX) published a peer-reviewed analysis in Frontiers in Cardiovascular Medicine, showing no cardiotoxicity in 90 patients treated with Annamycin across five trials. The study, evaluated by Cleveland Clinic, found no significant changes in left ventricular ejection fraction (LVEF) and no treatment-related cardiotoxicity. Annamycin is being evaluated in the MIRACLE trial for relapsed or refractory AML.

rttnews.com2 min